Veröffentlichungen 2001

1. Brix G, Ziegler SI, Bellemann ME, Doll J, Schosser R, Lucht R, Nosske D, Haberkorn U. Quantification of FDG utilization in the normal liver using dynamic PET: impact and modeling of the dual hepatic blood supply. J Nucl Med 2001;42:1265-1273.

2. Brix G, Henze M, Knopp MV, Lucht R, Doll J, Junkermann H, Hawighorst H, Haberkorn U. Comparison of Pharmacokinetic MR and [18F]Fluorodeoxyglucose PET in the diagnosis of breast cancer: Initial experience. Eur Radiol 2001;11:2058-2070.

3. Brust P, Haubner R, Friedrich A, Scheunemann M, Koufaki ON, Hauses M, Schackert G, Noll S, Noll B, Haberkorn U, Avril N, Schackert HK, Johannsen B. Comparison of [18F]FHPG and [124/125I]FIAU for their potential of monitoring gene therapy. Eur J Nucl Med 2001;28:721-729.

4. Delorme S, Haberkorn U, Kinscherf R, Zuna I, Bahner ML, van Kaick G. Changes of tumor vascularity during gene therapy monitored with color Doppler US. Ultrasound Med Biol 2001;27:1595-1603.

5. Dimitrakopoulou­-Strauss A, Strauss LG, Burger C. Quantitative PET­Studies in pretreated melanoma patients: A comparison of 6-(18F)fluoro­L-DOPA with 18F­-FDG and 15O­-Water using compartment and non­compartment analysis. J Nucl Med 2001;42:248-256.

6. Dimitrakopoulou-­Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechtersheimer G, Lehnert T. Dynamic PET­-18F-FDG Studies in patients with primary and recurrent soft tissue sarcomas:impact on diagnosis and correlation with grading. J Nucl Med 2001;42:713-720.

7. Haberkorn U. Positron emission tomography of non small cell lung cancer. Lung Cancer 2001;34/1002:S115-S121.

8. Haberkorn U, Altmann A. Imaging methods in gene therapy of cancer. Current Gene Ther 2001;1:163-182.

9. Haberkorn U, Schönberg S. Imaging of lung cancer with CT, MRT and PET. Lung Cancer 2001;34/1003:S13-S23.

10. Haberkorn U. PET in der Diagnostik zur Therapieplanung vor Tumoroperationen. Der Chirurg 2001;72:1010-1019.

11. Haberkorn U, Altmann A. Imaging techniques for gene therapy: SPECT, PET and MRI. J Pharmacy Practice 2001;14:383-396.

12. Haberkorn U. Gene therapy with sodium/iodide symporter in hepatocarcinoma. Exp Clin Endocrinol Diabetes 2001;109:60-62.

13. Haberkorn U, Kinscherf R, Krammer PH, Mier W, Eisenhut M. Investigation of a Potential Scintigraphic Marker of Apoptosis: Radioiodinated Z-Val-Ala-DL-Asp(O-Methyl)-fluoromethyl Ketone. Nucl Med Biol 2001;28:793-798.

14. Haberkorn U, Bellemann ME, Brix G, Kamencic H, Morr I, Traut U, Altmann A, Doll J, Blatter J, Kinscherf R. Apoptosis and changes in glucose metabolism after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med 2001;28:418-425.

15. Haberkorn U, Altmann A, Kamencic H, Morr I, Traut U, Henze M, Jiang S, Metz J, Kinscherf R. Glucose transport and apoptosis after gene therapy with HSV thymidine kinase. Eur J Nucl Med 2001;28:1690-1696.

16. Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, Peschke P, Kübler W, Debus J, Eisenhut M. Transfer of the human sodium iodine symporter gene enhances iodine uptake in hepatoma cells. J Nucl Med 2001;42:317-325.

17. Haberkorn U, Altmann A, Jiang S, Morr I, Mahmut M, Eisenhut M. Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur J Nucl Med 2001;28:633-638.

18. Hempel A, Henze M, Berghoff C, Garcia N, Ody R, Schröder J. PET findings and neuropsychological deficits in a case of Fahr`s disease. Psych Res Neuroim 2001;108(2):133-140.

19. Henze M, Hittel JP. Mucoepidermoid carcinomas of the salivary glands after high-dose radioiodine therapy. Laryngorhinootologie 2001;80:253-256.

20. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker D, Doll J, Mäcke H, Hofmann M, Debus J, Haberkorn U. PET imaging of somatostatin receptors using [68Ga]-DOTA-D-Phe1-Tyr3-Octreotide (DOTATOC): First results in meningioma patients. J Nucl Med 2001;42:1053-1056.

21. Hofmann M, Maecke H, Börner AR, Weckesser E, Schöffski P, Oei ML, Schumacher J, Henze M, Heppeler A, Meyer GJ, Knapp WH. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–1757.

22. Jiang S, Altmann A, Grimm D, Kleinschmidt JA, Schilling T, Germann C, Haberkorn U. Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther 2001;8:469-472.

23. Mattern J. Role of angiogenesis in drug resistance. Anticancer Res 2001;21:4265-4270.

24. Mattern J, Volm M. Clinical estimation of the growth rate of lung cancer. Anticancer Res 2001;21:4067-4070.

25. Mier W, Eritja R, Mohammed A, Haberkorn U, Eisenhut M. Synthesis and labeling of peptide nucleic acid oligomers conjugated to octreotate. J Labelled Cpd Radiopharm 2001;44:S954-S956.

26. Mier W, Haberkorn U, Eisenhut M. Synthesis and isolation of active esters of DOTA. J Labelled Cpd Radiopharm 2001;44:S814-S816.

27. Mier W, Rossmann M, Mohammed A, Haberkorn U, Eisenhut M. 3'-end labeling procedure for phosphorothioate oligonucleotides and oligonucleotide-conjugates. J Labelled Cpd Radiopharm 2001;44:S163-S166.

28. Rohrschneider WK, Hoffend J, Becker K, Darge K, Wunsch R, Clorius JH, Kooijman H, Tröger J. Statisch-dynamische MR-Urographie. Vergleich mit Ausscheidungsurographie und Szintigraphie bei experimentell induzierter Harntransportstörung (HTS). Radiologe 2001;41:154-167.

29. Schlemmer HP, Henze M, Herfarth K, Bachert P, Debus J, van Kaick G. Proton MR spectroscopy and 18F-FDG-PET for the assessment of suspicious lesions after brain tumor radiotherapy. J Magn Reson Imaging 2001;3:2288-2289.

30. Schuhmacher J, Klivenyi G, Kaul S, Henze M, Matys R, Hauser H, Clorius J. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol 2001;28:821-828.

31. Schuhmacher J, Kaul S, Klivenyi G, Junkermann H, Magener A, Henze M, Doll J, Haberkorn U, Amelung V, Bastert G. Immunoscintigraphy with Positron Emission Tomography: Gallium-68 Chelate Imaging of Breast Cancer Pretargeted with Bispecific Anti-MUC1/Anti-Ga Chelate Antibodies. Cancer Res 2001;61:3712-3717.

32. Schwarzbach M, Dimitrakopoulou­-Strauss A, Mechtersheimer G, Hinz U, Willeke F, Cardona S, Attigah N, Strauss LG, Herfarth C, Lehnert T. Assessment of soft tissue lesions suspicious for liposarcoma by F­18­ deoxyglucose (FDG) Positron Emission Tomography (PET). Anticancer Res 2001;21:3609-3614.

33. Strauss LG, Kontaxakis G, Dimitrakopoulou­-Strauss A. Performance characteristics of iterative image reconstruction for routine use in Positron Emission Tomography. Alasbimn 2001;3(13). www.alasbimnjournal.cl/revistas/13/
strauss.html.

34. Wu H, Dimitrakopoulou-Strauss A, Heichel TO, Lehner B, Bernd L, Ewerbeck V, Burger C, Strauss LG. Quantitative evaluation of skeletal tumors with dynamic Fluorine-18-Fluordeoxyglucose (FDG) PET: SUV in comparison to Patlak analysis. Eur J Nucl Med 2001;28:704-710.

35. Zhou X, Frohlich ED, Clorius JH, Haufe S. Functional and structural involvement of afferent and efferent glomerular arterioles in hypertension. Am J Kidney Dis 2001;37:1092-1097.

1. Ebert M, Henze M, Hipp P, Schad L. Chapter 3: Imaging – Nuclear Medicine. In: 3D Conformal Radiation Therapy - Multimedia Introduction to Methods and Techniques (ed.) Schlegel W, Mahr A, Springer Verlag, Berlin, Heidelberg, New York 2001.

2. Strauss LG, Dimitrakopoulou-Strauss A. Positronenemissionstomographie (PET) in der onkologischen Diagnostik und Therapieplanung. In: Onkologie: Grundlagen, Diagnostik, Therapie, Entwicklungen 1995, III-5, Band 1. (ed.) Zeller, zur Hausen. ecomed, Landsberg, 2001, pp 1-17.